These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 4098282)

  • 21. [Immunologic properties, aggregate content and half-life of various human i.v. gamma globulin preparations].
    Ring J; Duswald KH; Seifert J; Brendel W
    Langenbecks Arch Chir; 1976; Suppl():63-7. PubMed ID: 73997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the serologic response in cats to various antigens, using homologous and heterologous complement.
    Perryman LE; Olsen RG; Yohn DS
    Am J Vet Res; 1973 Dec; 34(12):1529-32. PubMed ID: 4128461
    [No Abstract]   [Full Text] [Related]  

  • 23. [The therapy with immunoglobulins. Structure, mechanisms of action and the intravenous use of gammaglobulin preparations (author's transl)].
    Schulte-Wissermann H; Schofer O; Dinkel E
    Immun Infekt; 1982 May; 10(3):98-109. PubMed ID: 6178676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Undegraded -globulin for intravenous therapy. A new preparation of immune serum globulin for intravenous administration.
    Stephan W; Hainski M; Payne JH; Ordonez GA; Shanbrom E
    Vox Sang; 1971 May; 20(5):469-78. PubMed ID: 4106555
    [No Abstract]   [Full Text] [Related]  

  • 25. [Preliminary trials and therapeutic results of subarachnoid administration of anti-tetanus human immunoglobulins].
    Rossano C; Giugliano F
    Minerva Anestesiol; 1970 Nov; 36(11):725-7. PubMed ID: 4100705
    [No Abstract]   [Full Text] [Related]  

  • 26. Intravenous gamma globulin. Metabolism of gamma globulin fragments in normal and agammaglobulinemic persons.
    Janeway CA; Merler E; Rosen FS; Salmon S; Crain JD
    N Engl J Med; 1968 Apr; 278(17):919-23. PubMed ID: 4171301
    [No Abstract]   [Full Text] [Related]  

  • 27. [Determination of residual pepsin in intravenous immunoglobulins].
    Reuge C
    Rev Fr Transfus Immunohematol; 1988 Feb; 31(1):61-3. PubMed ID: 3135567
    [No Abstract]   [Full Text] [Related]  

  • 28. [Intravenous administration of gamma globulin in idiopathic thrombocytopenic purpura].
    Sallerfors B; Persson S
    Lakartidningen; 1983 Nov; 80(45):4296-7. PubMed ID: 6197594
    [No Abstract]   [Full Text] [Related]  

  • 29. Intravenous plasmin-treated gammaglobulin treatment in immune thrombocytopenic purpura (ITP).
    Bierling P; Oksenhendler E; Duedari N
    Eur J Haematol; 1988 Aug; 41(2):192. PubMed ID: 2457511
    [No Abstract]   [Full Text] [Related]  

  • 30. Behaviour of serum immunoglobulins during and after intravenous administration of gamma-globulins in patients with antibody deficiency syndrome.
    Gravina E; Gravina-Sanvitale G
    Boll Ist Sieroter Milan; 1974; 53(1):suppl:268. PubMed ID: 4136556
    [No Abstract]   [Full Text] [Related]  

  • 31. [Hemotherapy in due proportion. II. Clinical administration of plasma fractions].
    Hässig A; Barandun S; Bucher U; Lundsgaard-Hansen P
    Dtsch Med Wochenschr; 1974 May; 99(18):962-6. PubMed ID: 4134560
    [No Abstract]   [Full Text] [Related]  

  • 32. [The use of intravenous gamma globulin in malignant hematologic diseases].
    Garay GE
    Medicina (B Aires); 1989; 49(6):621-7. PubMed ID: 2484842
    [No Abstract]   [Full Text] [Related]  

  • 33. Complement fixation by aggregated IgE through alternate pathway.
    Ishizaka T; Sian CM; Ishizaka K
    J Immunol; 1972 Mar; 108(3):848-51. PubMed ID: 4551855
    [No Abstract]   [Full Text] [Related]  

  • 34. Differences in immunoglobulin preparations for intravenous use: a comparison of six products.
    Greenbaum BH
    Am J Pediatr Hematol Oncol; 1990; 12(4):490-6. PubMed ID: 1704686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Studies on the elimination of fermentally disintegrated gamma globulin from the blood plasma].
    Mai K; Bläker F
    Z Immunitatsforsch Exp Klin Immunol; 1971 Aug; 142(2):173-82. PubMed ID: 4105637
    [No Abstract]   [Full Text] [Related]  

  • 36. Immune mechanisms of reversed type reaginic hypersensitivity.
    Ishizaka K; Ishizaka T
    J Immunol; 1969 Sep; 103(3):588-95. PubMed ID: 4185043
    [No Abstract]   [Full Text] [Related]  

  • 37. Reaction of sheep slow and fast -globulins with sheep complement.
    Jonas WE; Davey J
    Res Vet Sci; 1973 Jan; 14(1):115-7. PubMed ID: 4122511
    [No Abstract]   [Full Text] [Related]  

  • 38. An evaluation of commercial Coombs reagents and their anti-complement activity.
    Bowlen VJ
    Am J Med Technol; 1972 Oct; 38(10):381-6. PubMed ID: 4117024
    [No Abstract]   [Full Text] [Related]  

  • 39. [Localization of the specific neutralizing activity in poliomyelitis antibodies treated with papain, pepsin and reducing agents].
    Voiculescu C; Mitrică N; Dinculescu M; Georgescu C; Radu J
    Stud Cercet Inframicrobiol; 1970; 21(1):43-7. PubMed ID: 4195444
    [No Abstract]   [Full Text] [Related]  

  • 40. It is posterior reversible encephalopathy, and not stroke, after intravenous gamma globulin.
    Sarma GR
    Neurol India; 2011; 59(3):490; discussion 490. PubMed ID: 21743203
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.